Medically treated patients with mild or no symptoms of gastroesophageal reflux disease ( GERD ) are at higher risk for developing esophageal cancer than those with severe GERD symptoms, according to a University of Pittsburgh study published in the current issue of Archives of Surgery. Many patients who develop adenocarcinoma, a common form of esophageal cancer, are unaware that they have Barrett's esophagus - a change in the cells lining the esophagus often due to repeated stomach acid exposure. In some cases, Barrett's esophagus develops into esophageal cancer. "Typically, patients with severe GERD symptoms are screened for Barrett's esophagus, but those with mild or absent symptoms are not. Unfortunately, many patients who develop adenocarcinoma don't know that they have Barrett's esophagus until it has transformed into cancer and become advanced, leading to obstruction, " said principal investigator Blair A.
The ultimate source of some cancers is embryonic cells. Research published in the June 24th Cell, a Cell Press publication, traces the precursor of deadly esophageal cancers to leftover embryonic cells found in all adults. Some people with gastric reflux disease have a greater risk of developing esophageal cancer. These patients often have Barrett's esophagus, a condition in which intestinal-like cells appear in the esophagus. Esophageal cancers are difficult to treat and, together with gastric adenocarcinomas, kill more than a million people each year. "A lot of cancers you can do little about, and new drugs are approved based on their ability to extend life by one or two months, " said the senior author of this study, Frank McKeon of Harvard Medical School and the Genome Institute of Singapore.
First Patient Enrolled And Treated In The U.S. For EndoGastric Solutions' Randomized Study Of Transoral Incisionless Fundoplication TIF
EndoGastric Solutions (EGS), the leader in the emerging field of Natural Orifice Surgery (NOS), today announced that the first patient has been enrolled and treated in the RESPECT study (Randomized EsophyX vs. Sham/Placebo Controlled Trial). The RESPECT trial was designed by co-principle investigators Dr. John Hunter, Chairman of Surgery, Oregon Health & Science University, and Dr. Peter Kahrilas, Professor of Medicine-Gastroenterology, Northwestern University. The first patient in the study was enrolled by Dr. Reginald Bell, Assistant Clinical Professor of Surgery, University of Colorado Health Sciences Center. Designed to generate the first U.S. Level 1 evidence supporting transoral incisionless fundoplication (TIF® ) surgery, the study randomizes patients between TIF and sham, and omeprazole and placebo.
University of Rochester Medical Center researchers have pinpointed two genes that are amplified in the worst cases of esophageal cancer, providing data to support a new investigational treatment that targets those same genes. The study, led by Tony Godfrey, Ph.D., a research associate professor of Surgery at the James P. Wilmot Cancer Center at URMC, was published by the journal Clinical Cancer Research. It explores the chromosomal abnormalities that influence poor survival rates of esophageal adenocarcinoma (EAC), the more common type of esophageal cancer which occurs at the junction of the stomach and esophagus. Considered uncommon 20 years ago, the incidence of EAC has grown faster than any tumor type in the United States, Godfrey said. Health authorities believe high rates of obesity and gastroesophageal reflux disease ( GERD ) contribute to the rising numbers.
Gastroesophageal reflux (GER) is a common problem in mechanically ventilated patients and contributes to the development of esophageal mucosal injury and even erosive esophagitis. The relationship between percutaneous endoscopic gastrostomy (PEG) and subsequent development of GER is complex and not well understood. A research article published in the World Journal of Gastroenterology addresses this question. The research team from Greece explored the factors that interfere with failure of PEG to reduce GER in critically ill, mechanically ventilated patients. A cohort of 29 consecutive mechanically ventilated patients undergoing PEG was prospectively evaluated. The patients were divided into 2 groups based on whether GER decreased to less than 4% (responders, RESP group) or remained unchanged or worsened (non-responders, N-RESP group) after PEG placement.